



Online Resource 1 TENAYA and LUCERNE study design. Randomized, double-masked, multicenter, phase 3 trials designed to evaluate the efficacy, safety, and durability of faricimab dosed up to every 16 weeks (Q16W) compared with aflibercept every 8 weeks (Q8W) in patients with neovascular age-related macular degeneration. Best-corrected visual acuity (BCVA) was measured using the Early Treatment Diabetic Retinopathy Study visual acuity chart at a starting distance of 4 m.

*At weeks 20 and 24, based on BCVA and central subfield thickness (CST) criteria and investigator's evaluation.

†Change in BCVA from baseline at week 48, averaged over weeks 40, 44, and 48.

D day, *PTI* personalized treatment interval, *Q12W* every 12 weeks, *R* randomization

Reprinted from The Lancet, 399, Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al, Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials, 729-740., Copyright (2022), with permission from Elsevier.